CareDx (CDNA)
NASDAQ:CDNA
Want to see CDNA full AI Analyst Report?
CDNA Stock Chart & Stats
$21.42
$0.67(2.95%)
At close: 4:00 PM EST
$21.42
$0.67(2.95%)
Day’s Range― - ―
52-Week Range$10.96 - $23.24
Previous CloseN/A
Volume177.07K
Average Volume (3M)1.12M
Market Cap
$1.11B
Enterprise Value$1.01B
Total Cash (Recent Filing)$187.18M
Total Debt (Recent Filing)$17.84M
Price to Earnings (P/E)79.0
Beta1.29
Next Earnings
Aug 11, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding51,659,480
10 Day Avg. Volume957,989
30 Day Avg. Volume1,123,784
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit3.55
Enterprise Value/Ebitda99.82
Forecast
1Y Price Target
$24.73Price Target Upside15.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.75
Revenue Forecast (FY)$432.02M
Bulls Say, Bears Say
Bulls Say
Demand-driven Revenue GrowthRising test volumes across heart, lung and kidney testing combined with stronger patient and digital solutions sales led revenue to outperform analyst expectations, signaling sustained demand for core services.
New Product Pipeline ExpansionAdvancement of the AlloHeme molecular surveillance test could enable earlier relapse detection and open opportunities in cell therapy and oncology markets, creating a material new growth avenue.
Strategic Refocus And Capital RedeploymentDivestiture of the lab products unit sharpens focus on core transplant testing and digital services and frees cash that can fund targeted acquisitions or be returned to shareholders.
Bears Say
Accounting Loss And Profitability ConcernsA reported net loss under generally accepted accounting principles highlights ongoing profitability and cash-flow risks despite positive adjusted earnings, which may weigh on investor confidence.
Coverage Policy And Reimbursement RiskUncertainty around a proposed local coverage policy for transplant testing could materially reduce reimbursement and create a significant revenue headwind if finalized as drafted.
Near-term Margin Pressure From Systems InvestmentsMaterial investments in enterprise systems and electronic health record integration are expected to pressure near-term profitability even if they strengthen long-term operations.
CareDx News
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $10.96 and its highest was $23.24 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $1.11B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Aug 11, 2026 which is in 100 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Apr 28, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.134 by $0.206.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is 0.24.
How many shares outstanding does CareDx have?
CareDx has 51,659,480 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of $0.34 in its last earnings report, beating expectations of $0.134. Following the earnings report the stock price went down -5.066%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.73 (15.44% Upside)
$24.73 (15.44% Upside)
Hedge Fund Trend
Increased
By 201.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.91%
12-Months-Change
Fundamentals
Return on Equity
-2.61%
Trailing 12-Months
Asset Growth
-16.05%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
CDNA Company Deck
CDNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong top-line growth, substantial margin and EBITDA improvement, raised full‑year guidance, a strategic simplification via a Lab Products divestiture (expected ~$160M net proceeds), and a targeted acquisition (Navaris) that expands addressable markets with strong clinical evidence and favorable reimbursement. Challenges include modest profitability and declining trends in the Lab Products segment prior to divestiture, revenue recognition timing noise, reimbursement/LCD risk (~$7.5M modeled headwind), elevated operating expenses and uncertainty in transplant procedure volumes, and integration/scale risks for Navaris and the product carve-out. On balance, the positive growth, improved profitability, cash position, and strategic actions outweigh the execution and timing risks discussed on the call.View all CDNA earnings summariesCDNA Stock 12 Month Forecast
Average Price Target
$24.73
▲(15.44% Upside)
Technical Analysis
Ownership Overview
5.09% Insiders
20.52% Mutual Funds
7.68% Other Institutional Investors
44.50% Public Companies and
Individual Investors